Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price hit a new 52-week high on Monday . The company traded as high as $48.86 and last traded at $47.68, with a volume of 237795 shares changing hands. The stock had previously closed at $47.79.
Gemini Therapeutics Price Performance
The stock has a market capitalization of $2.07 billion, a P/E ratio of -47.79 and a beta of -0.12. The firm has a 50 day moving average of $46.99 and a 200-day moving average of $43.53.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- Investing In Automotive Stocks
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- 3 Stocks to Consider Buying in October
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How Technical Indicators Can Help You Find Oversold Stocks
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
